Background Early-phase and preclinical studies suggest that moxifloxacin-containing regimens
could allow for effective 4-month treatment of uncomplicated, smear-positive pulmonary …

Whole genome sequencing (WGS) promises to be transformative for the practice of clinical
microbiology, and the rapidly falling cost and turnaround time mean that this will become a …

The story of antituberculosis chemotherapy is a miniature of the history of anti-infective
chemotherapy. In the first half of the 20th century the problem of tuberculosis appeared insoluble: …

About 1·3 million people died of tuberculosis in 2012, despite availability of effective drug
treatment. Barriers to improvements in outcomes include long treatment duration (resulting in …

Background: Antibiotic choices for pleural infection are uncertain as its bacteriology is poorly
described. Methods: Pleural fluid from 434 pleural infections underwent standard culture …

Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …

Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on pharmacokinetic,
toxicity, and cost considerations. Available data in mice and humans showed that an …

Drug-resistant Mycobacterium tuberculosis is a major threat to public health. In clinical practice,
a limited number of resistance mutations in a short sequence of the beta subunit of RNA …

The 600-mg once daily dose of rifampicin plays a key role in tuberculosis treatment. The
evidence underpinning this dose is scant. A review of the historical literature identified 3 strands …

Since the publication of the last edition of Principles and Practice of Clinical Bacteriology,
our understanding of bacterial genetics and pathogenicity has been transformed due to the …